Dolasetron

Definition
This section has been translated automatically.

5-HT3 antagonist, antiemetic.

Pharmacodynamics (Effect)
This section has been translated automatically.

Selective, competitive binding to 5-HT3 receptors in the brain, among other places. As a result, serotonin can no longer bind to its binding sites at the 5-HT3 receptors and exert its effect. This directly prevents the development of nausea and vomiting, among other things.

You might also be interested in

Dermatology

Neurofibroma

Most frequent neurogenic tumour, which occurs solitary or as part of neurofibromatosis .

Advertisment

Indication
This section has been translated automatically.

Prophylaxis of cytostatic-induced nausea and vomiting.

Pregnancy/nursing period
This section has been translated automatically.

Strictest indication for use during pregnancy. Use only if it can be assumed that the expected therapeutic benefit for the patient outweighs any risk to the fetus. Lactation: Do not use during lactation or weaning before therapy, as it is not known whether the active substance passes into breast milk (insufficient data available).

Dosage and method of use
This section has been translated automatically.

Nausea & vomiting due to cytostatic chemotherapy: Approximately 30 min before each chemotherapy application 100 mg i.v. Alternatively: 60 min before each chemotherapy treatment 200 mg p.o.
Delayed onset of nausea & vomiting: 1 time/day 200 mg p.o.

Undesirable effects
This section has been translated automatically.

Cutaneous ADRs: Occasional allergic or anaphylactic reactions. Slight exanthematic skin changes, flush and edema. Local reactions at the infusion site (burning, erythema, wheals).
Extracutaneous ADRs: Headache (about 20-40% of patients), dizziness (10-15%), hypertension, lymphadenopathy, gastrointestinal disorders such as constipation or diarrhea (10-16%), arthralgia, fatigue (20-25%), flu-like symptoms with fever (3-5%) and chills.